单期增强CT能否鉴别神经内分泌肿瘤肝转移的组织学亚型——与镓-68 DOTATATE PET/CT表现的相关性
研究纳入2017年12月至2019年4月神经内分泌肿瘤肝转移患者,回顾性分析单期增强CT定性及定量特征与镓-68 DOTATATE PET/CT的相关性。胃肠来源肝转移多呈不均匀强化且96.72%为低密度,胰腺来源多呈高密度(63.26%);肿瘤CT值、肿瘤-肝脏比及肿瘤-主动脉比在亚组间有显著差异,而SUVmax、SUVmean及MTV无显著差异。
要点
- 胃肠来源NET肝转移96.72%(n=59)呈低密度,胰腺来源63.26%(n=31)呈高密度,强化方式差异有统计学意义(p<0.001)。
- 胃肠来源NET肝转移常见不均匀强化,显著高于胰腺及肺来源(p<0.001)。
- 肿瘤-主动脉比在胰腺来源NET肝转移中显著更高(p<0.001);SUVmax、SUVmean及MTV亚组间无显著差异。
关键影像表现/征象
- 胃肠来源NET肝转移常呈不均匀强化,显著高于胰腺及肺来源NET肝转移(p<0.001)。
- 胃肠来源NET肝转移96.72%(n=59)呈低密度,胰腺来源最常见表现为高密度(63.26%,n=31),强化方式差异有统计学意义(p<0.001)。
- 肿瘤CT值在组间差异有统计学意义(p<0.001);肿瘤-肝脏比在胃肠与胰腺来源及胰腺与肺来源NET肝转移间差异有统计学意义(p<0.001);肿瘤-主动脉比在胰腺来源NET肝转移中显著更高(p<0.001)。
- SUVmax、SUVmean及MTV在亚组间无显著差异;肿瘤-肝脏比与SUVmean呈弱正相关。
诊断标准与关键数值
- 137个NET肝转移分为三组:胰腺来源49个(35.7%)、胃肠来源60个(44.5%)、肺来源26个(18.9%)。
- 定量指标包括肿瘤CT值、肿瘤-肝脏比[T-L=(肿瘤-肝脏)/肝脏]及肿瘤-主动脉比[T-A=(肿瘤-主动脉)/主动脉],取肝脏内镓-68 DOTATATE摄取最高的病灶计算。
- PET/CT定量指标包括代谢肿瘤体积(MTV)、最大标准化摄取值(SUVmax)及平均标准化摄取值(SUVmean)。
临床应用与阅片要点
- 阅片时可关注肝转移灶的强化方式(均匀/不均匀)及密度(高/低密度),以辅助推测原发肿瘤来源。
- 测量肿瘤CT值并计算肿瘤-肝脏比和肿瘤-主动脉比,有助于区分胰腺与胃肠来源NET肝转移。
- PET/CT的SUVmax、SUVmean及MTV在组织学亚组间无显著差异,不宜单独用于鉴别亚型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the usefulness of a single-phase contrast-enhanced CT to differentiate subtypes of neuroendocrine tumour (NET) liver metastases and to evaluate the correlation between CT features and Ga-68 DOTATATE positron emission tomography/CT (PET/CT) findings.
METHODS: Between December 2017 and April 2019 patients with liver metastases of neuroendocrine tumours who underwent CT and Ga-68 DOTATATE PET/CT were enrolled in the study. All patients involved in the study had undergone a standardised single-phase contrast-enhanced CT. Whole body PET/CT images were obtained with a combined PET/CT scanner. All CT images were retrospectively analysed by two radiologists. Enhancement patterns of lesions were assessed. For quantitative examination; CT attenuation values of metastatic lesions, liver parenchyma and aorta were measured using a freehand ROI and tumour-to-liver ratio [T-L = (Tumour-Liver) / Liver] and tumour-to-aorta ratio [T-A = (Tumour-Aorta) / Aorta] were calculated. The lesion with the highest Ga-68 DOTATATE uptake in the liver was used for calculations. The metabolic tumour volume (MTV), maximum standardised uptake value (SUV max) and SUV mean were calculated for the target liver lesion.
RESULTS: A total of 137 NET liver metastases divided into in three groups: 49 (35.7%) pancreatic, 60 (44.5%) gastroenteric and 26 (18.9%) lung NET liver metastases were analysed. Gastroenteric NET metastases often showed heterogeneous enhancement which was significantly higher than in the pancreas and lung NET liver metastases (p < 0.001). 96.72% (n = 59) of the gastroenteric NET liver metastases were hypoattenuating whereas the most frequent presentation for the pancreatic group was hyperattenuation (63.26%,n = 31). The difference in enhancement patterns of the liver metastases was statistically significant (p < 0.001) with respect to the location of the primary tumour. For quantitative analysis; tumour CT values were significantly different between the groups (p < 0.001). The T-L ratio was statistically different between gastroenteric and pancreatic NET liver metastases and pancreatic and lung NET groups (p < 0.001). The T-A ratio was significantly higher in the pancreatic NET metastases (p < 0.001). SUVmax, SUVmean and MTV values, however, were not significantly different between the subgroups. There was a weak positive correlation between T-L ratio and SUV meanvalues.
CONCLUSION: We noticed statistically significant differences in both qualitative and quantitative CT features between histologic subgroups of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT.
ADVANCES IN KNOWLEDGE: Our study will be the first in the literature which extensively focus on assessing the CT features of liver metastases of NETs at a single phase CT and Ga-68DOTATATE PET/CT. As the different histological subtypes of NET liver metastases exhibit different clinical outcomes, these features might help to identify the primary tumour to provide optimal treatment.
引用
- Gulpinar B, Peker E, Soydal C, et al. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings. Br J Radiol. 2020. PMID: 31922897. doi:10.1259/bjr.20190735
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。